// App-Quantinova.ai

310 : Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC).

Researchers

Presenter

  • Ghassan K. Abou-Alfa

Principal Investigators

  • Tim Meyer

  • Jie Zhang

  • Scott Sherrin

  • Amin Yaqubie

  • Alison Clemens ONeill

  • Feng Xu

  • Lisa D Eli

  • James J. Harding

  • Eileen Mary O'Reilly

  • Alshad S. Lalani

  • Richard Bryce

  • John Dozier Gordan

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The Royal Marsden Hospital, London, United Kingdom

  • Puma Biotechnology Inc., Los Angeles, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Puma Biotechnology Inc., Los Angeles, CA

  • University of California, San Francisco, San Francisco, CA

Locations

  • United States

  • United Kingdom

Companies

  • Puma Biotechnology,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Everolimus

  • Neratinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01953926

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved